Progress Versus Precision

Challenges in Clinical Trial Design for Left Ventricular Assist Devices

Michael K. Parides, Alan J. Moskowitz, Deborah D. Ascheim, Eric A. Rose, Annetine C. Gelijns

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

New left ventricular assist devices promise fewer adverse events but, currently, only minor improvements in survival. Small (survival) treatment effects, limited patient populations, and the increasing number of left ventricular assist devices in development challenge the efficient conduct of premarketing trials (especially in destination therapy) and, maybe more importantly, hamper innovation. Novel trial designs would facilitate this process. Among a range of trial designs, we opt for small randomized trials, which would preserve the advantages of randomization and also allow for a shorter enrollment period. We also advocate an evidence shift toward postmarketing studies, with the Interagency Registry of Mechanically Assisted Circulatory Support providing a robust infrastructure.

Original languageEnglish (US)
Pages (from-to)1140-1146
Number of pages7
JournalAnnals of Thoracic Surgery
Volume82
Issue number3
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Heart-Assist Devices
Clinical Trials
Survival
Random Allocation
Registries
Therapeutics
Population

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Progress Versus Precision : Challenges in Clinical Trial Design for Left Ventricular Assist Devices. / Parides, Michael K.; Moskowitz, Alan J.; Ascheim, Deborah D.; Rose, Eric A.; Gelijns, Annetine C.

In: Annals of Thoracic Surgery, Vol. 82, No. 3, 01.09.2006, p. 1140-1146.

Research output: Contribution to journalReview article

Parides, Michael K. ; Moskowitz, Alan J. ; Ascheim, Deborah D. ; Rose, Eric A. ; Gelijns, Annetine C. / Progress Versus Precision : Challenges in Clinical Trial Design for Left Ventricular Assist Devices. In: Annals of Thoracic Surgery. 2006 ; Vol. 82, No. 3. pp. 1140-1146.
@article{37b8077d4f6646fea4f37ba9fe7d5541,
title = "Progress Versus Precision: Challenges in Clinical Trial Design for Left Ventricular Assist Devices",
abstract = "New left ventricular assist devices promise fewer adverse events but, currently, only minor improvements in survival. Small (survival) treatment effects, limited patient populations, and the increasing number of left ventricular assist devices in development challenge the efficient conduct of premarketing trials (especially in destination therapy) and, maybe more importantly, hamper innovation. Novel trial designs would facilitate this process. Among a range of trial designs, we opt for small randomized trials, which would preserve the advantages of randomization and also allow for a shorter enrollment period. We also advocate an evidence shift toward postmarketing studies, with the Interagency Registry of Mechanically Assisted Circulatory Support providing a robust infrastructure.",
author = "Parides, {Michael K.} and Moskowitz, {Alan J.} and Ascheim, {Deborah D.} and Rose, {Eric A.} and Gelijns, {Annetine C.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.athoracsur.2006.05.123",
language = "English (US)",
volume = "82",
pages = "1140--1146",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Progress Versus Precision

T2 - Challenges in Clinical Trial Design for Left Ventricular Assist Devices

AU - Parides, Michael K.

AU - Moskowitz, Alan J.

AU - Ascheim, Deborah D.

AU - Rose, Eric A.

AU - Gelijns, Annetine C.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - New left ventricular assist devices promise fewer adverse events but, currently, only minor improvements in survival. Small (survival) treatment effects, limited patient populations, and the increasing number of left ventricular assist devices in development challenge the efficient conduct of premarketing trials (especially in destination therapy) and, maybe more importantly, hamper innovation. Novel trial designs would facilitate this process. Among a range of trial designs, we opt for small randomized trials, which would preserve the advantages of randomization and also allow for a shorter enrollment period. We also advocate an evidence shift toward postmarketing studies, with the Interagency Registry of Mechanically Assisted Circulatory Support providing a robust infrastructure.

AB - New left ventricular assist devices promise fewer adverse events but, currently, only minor improvements in survival. Small (survival) treatment effects, limited patient populations, and the increasing number of left ventricular assist devices in development challenge the efficient conduct of premarketing trials (especially in destination therapy) and, maybe more importantly, hamper innovation. Novel trial designs would facilitate this process. Among a range of trial designs, we opt for small randomized trials, which would preserve the advantages of randomization and also allow for a shorter enrollment period. We also advocate an evidence shift toward postmarketing studies, with the Interagency Registry of Mechanically Assisted Circulatory Support providing a robust infrastructure.

UR - http://www.scopus.com/inward/record.url?scp=33747366081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747366081&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2006.05.123

DO - 10.1016/j.athoracsur.2006.05.123

M3 - Review article

VL - 82

SP - 1140

EP - 1146

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 3

ER -